Print Page  Close Window    

2019 Press Releases

2019 | 2018 | 2017 | 2016 | 2015

La Jolla Pharmaceutical Company Appoints Darryl Wellinghoff as Chief Commercial Officer

03/11/19

SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More

La Jolla Pharmaceutical Company to Present at the 39th Annual Cowen Healthcare Conference

03/07/19

SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Highlights Recent Corporate Progress and Key Objectives

03/04/19

SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More

La Jolla Pharmaceutical Company to Release Fourth Quarter and Full Year 2018 Financial Results on March 4, 2019

02/25/19

SAN DIEGO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More

La Jolla Pharmaceutical Company Announces Data Presentations at the Society of Critical Care Medicine’s 48th Critical Care Congress

02/14/19

New Data on GIAPREZA™ (angiotensin II) to be Presented in Oral Sessions at the Society of Critical Care Medicine’s 48th Critical Care Congress SAN DIEGO, Feb. 14, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announ

Read More

La Jolla Pharmaceutical Company Highlights Recent Corporate Progress and Key Objectives

01/07/19

- Fourth-Quarter 2018 Net Sales of GIAPREZA Were Approximately $4.2 Million, Up 20% from the Third Quarter of 2018 - - Full-Year 2019 Net Sales Guidance for GIAPREZA of $24 Million to $28 Million - - Decision on GIAPREZA MAA by EMA Expected in Ju

Read More

La Jolla Pharmaceutical Company to Present at the 37th Annual J.P. Morgan Healthcare Conference

01/04/19

SAN DIEGO, Jan. 04, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More